- Home
- About
- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- Events
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefTM
- Tools
- Audio/Video/Infographics
Archives
Biomarkers In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
About This Event
Biomarkers In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Background
Clinical complications associated with autosomal polycystic kidney disease (ADPKD) appear gradually over time and are associated with the progressive development of cysts, kidney enlargement, and loss of renal function.1 The clinical course of ADPKD is marked by a long course of stable kidney function, despite the relentless expansion of kidney volume due to the growth of cysts.1 Height adjusted total kidney volume (Ht-TKV) has been recognized as a prognostic biomarker of cyst burden and disease severity.2 Can biomarker data provide additional information to improve prognostication for patients with ADPKD? Is it possible to create a biomarker profile to phenotype patients with ADPKD?
Did You Know?- Tubular secretory clearance may be compromised before detectable changes in GFR in patients with ADPKD.3
- In this cutting-edge webinar, we will discuss the most current data on biomarkers in ADPKD, focusing on those that are most validated in the literature.
- The different types of biomarkers (i.e., urine, serum, etc.) and how they can be utilized to understand ADPKD progression
- Key biomarkers associated with prognostication and how these biomarkers might be used to evaluate ADPKD disease progression
- Current gaps in the literature and potential next steps for future research in ADPKD biomarkers will be discussed
- Halvorson CR et al. Int J Nephrol Renovasc Dis. 2010; 3: 69-83.
- Irazabal MV et al. JASN. 2015; 26: 160-172.
- Wang K et al. CJASN. 2020; 15: 80–88.
Featuring
Pranav Garimella, MBBS, MPH, FASN
Assistant Professor of MedicineUniversity of California San Diego*
Dr. Pranav Garimella is board-certified nephrologist and assistant professor and director of the dialysis outreach program in the department of medicine and nephrology at UC San Diego. He received his training in India, Chicago, and completed his fellowship at Tufts University, training in clinical nephrology with a focus on polycystic kidney disease with Dr. Ron Perrone. His research endeavors have led to multiple NIH-funded studies and numerous peer-reviewed publications on the topic of kidney diseases. He has an ongoing NIH grant for his research elucidating aspects of kidney disease and has been the recipient of a multitude of teaching and clinical excellence awards. He is also involved in initiatives to develop programs specifically targeted at minority populations in an effort to improve health literacy and potentially clinical outcomes.
Kelly Reed, PhD
Nephrology Senior Clinical & Scientific LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Kelly Reed, PhD, joined Otsuka in 2012 and is currently a Senior Clinical & Scientific Liaison on our Nephrology East Team. Dr Reed has collaborated with several national professional organizations and healthcare systems providing educational presentations on hyponatremia and Autosomal Dominant Polycystic Kidney Disease (ADPKD). She has been a leader in resource development for the MSL team, co-led the nephrology MSL new hire training program during expansion and served as a mentor to several MSL new hires. Dr Reed earned her doctorate from Virginia Commonwealth University in Richmond, Virginia and completed her clinical internship at the Mailman Center for Child Development in Miami, Florida, followed by a two year fellowship at Cincinnati Children’s Hospital Medical Center.
Marla Dallal, PharmD, RPH
Nephrology Clinical & Scientific LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Marla Dallal, PharmD, RPH is a Clinical & Scientific Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.
*Dr Garimella is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Drs Reed and Dallal are employees of OPDC.
If you would like to register for the 3:00 pm to 4:00 pm EDT broadcast, please click below:
Registration
Related Resources
-
Voices From The Community Episode 20 – Overview of IgA Nephropathy
Audio/Podcast December 14, 2022In this podcast, Dr Edgar Lerma will present an overview of IgA nephropathy and a stepwise approach to identify and diagnose patients.
-
A Look Back On 2022 Content, Themes, & Resources
Article December 5, 2022As we approach the new year, it’s an ideal time to look back over the past year and celebrate the many developments and progress made in overcoming barriers, improving the…
-
ADPKD Centers of Excellence Program – PKD Foundation
Downloadable Resource July 15, 2022This downloadable resource provides an overview of the PKD Foundation’s Centers of Excellence Program.
Related Events
-
Cooking Demo With Chef Duane: Three Tasty CKD & PKD Friendly Recipes
January 31 from 12:00 pm to 1:00 pm -
Panel Discussion – Racial Disparities In Access To Renal Transplantation
February 14 from 12:00 pm to 1:00 pm
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2023 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.